Clinical Trial News and Research

RSS

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

A recent multicenter clinical trial of atorvastatin, a type of cholesterol-lowering drug, found that although the drug did not inhibit plasma HIV RNA levels, it did inhibit expression of cellular markers of immune activation and inflammation in patients with HIV infection.

17 Feb 2011

Study finds poor security practices in clinical trial file sharing methods

Patients who participate in clinical trials expect that their personal information will remain confidential, but a recent study led by Dr. Khaled El-Emam, Canada Research Chair in Electronic Health Information at the CHEO Research Institute, found that the security practices used to transfer and share sensitive files were inadequate.

17 Feb 2011

Sonablate HIFU device is now available in Brazil to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 medical device, announces that HIFU with the Sonablate is available to prostate cancer patients for the first time in Brazil at Hospital Nossa Senhora das Gracas in Curitiba, capital city of the state of Parana in southern Brazil.

17 Feb 2011

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Oncolytics Biotech Inc. announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin.

16 Feb 2011

Allergan receives FDA approval for expanded use of LAP-BAND System in obese adults

Allergan, today announced the U.S. Food and Drug Administration approved the expanded use of the LAP-BAND System, Allergan's gastric band, for adults with obesity who have failed more conservative weight reduction alternatives, such as diet and exercise and pharmacotherapy, and have a Body Mass Index of 30-40 and at least one obesity related comorbid condition.

16 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

Patient on artificial heart receives heart and kidney transplant

Charles Okeke, the Phoenix husband and father of three, made headlines in May 2010 when he became the first patient in the U.S. to be discharged from a hospital with an artificial heart. With the latest technology, the "Freedom Driver," the man without a heart was able to resume his family life and to be free of the confines of a hospital room.

16 Feb 2011

UT Southwestern treats breast-cancer patient with Accuray CyberKnife System

Breast-cancer patient Kristin Wiginton is the first to be treated at UT Southwestern Medical Center with high-beam radiation using the Accuray CyberKnife System, which offers improved cosmetic results, less radiation exposure to surrounding tissue and a shorter treatment period.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

AMT 2010 total net income increases to EUR 1.4 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.

16 Feb 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

Endosense announces completion of enrollment in EFFICAS I clinical study

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.

16 Feb 2011

Researchers identify cell of origin for sarcoma

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published today as the Featured Article in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start.

16 Feb 2011

Leading foundations support Australian diabetes treatment

Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US$140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that has the potential to transform the treatment of Type 1 diabetes.

15 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

The Almac Group announced today that Graham Nicholls, Director of Biostatistics for Almac's Clinical Technologies business unit, will be speaking at the Clinical Trial Supply Europe conference held in Barcelona, Spain, 22-23 February 2011.

15 Feb 2011

Clinical Trial News and Research

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

Study finds poor security practices in clinical trial file sharing methods

Sonablate HIFU device is now available in Brazil to treat prostate cancer

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Astellas, AVEO enter development, commercialization agreement for tivozanib

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Allergan receives FDA approval for expanded use of LAP-BAND System in obese adults

Flu vaccine update

Patient on artificial heart receives heart and kidney transplant

UT Southwestern treats breast-cancer patient with Accuray CyberKnife System

CTI's fourth quarter net loss increases to $34.1 million

AMT 2010 total net income increases to EUR 1.4 million

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Endosense announces completion of enrollment in EFFICAS I clinical study

Researchers identify cell of origin for sarcoma

Leading foundations support Australian diabetes treatment

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery